178 related articles for article (PubMed ID: 28196312)
1. Severe Venlafaxine Withdrawal Successfully Treated With a Short Course of Duloxetine.
Cutler N
Prim Care Companion CNS Disord; 2017 Feb; 19(1):. PubMed ID: 28196312
[No Abstract] [Full Text] [Related]
2. First-Trimester Pregnancy Exposure to Venlafaxine or Duloxetine and Risk of Major Congenital Malformations: A Systematic Review.
Lassen D; Ennis ZN; Damkier P
Basic Clin Pharmacol Toxicol; 2016 Jan; 118(1):32-6. PubMed ID: 26435496
[TBL] [Abstract][Full Text] [Related]
3. Venlafaxine-Induced Bruising: A Case Report.
Carpenter JE; Fombi J; Udoka O; Holder-Perkins V
Prim Care Companion CNS Disord; 2016; 18(3):. PubMed ID: 27722026
[No Abstract] [Full Text] [Related]
4. Duloxetine lessens joint pain in early-stage breast cancer.
Tanday S
Lancet Oncol; 2017 Jan; 18(1):e10. PubMed ID: 27989429
[No Abstract] [Full Text] [Related]
5. Venlafaxine induced akathisia: a case report.
Ceylan ME; Evrensel A
Trends Psychiatry Psychother; 2016; 38(2):117. PubMed ID: 27409139
[No Abstract] [Full Text] [Related]
6. Differential inhibition of cardiac and neuronal Na(+) channels by the selective serotonin-norepinephrine reuptake inhibitors duloxetine and venlafaxine.
Stoetzer C; Papenberg B; Doll T; Völker M; Heineke J; Stoetzer M; Wegner F; Leffler A
Eur J Pharmacol; 2016 Jul; 783():1-10. PubMed ID: 27130441
[TBL] [Abstract][Full Text] [Related]
7. Comparative study of the effects of venlafaxine and duloxetine on chemotherapy-induced peripheral neuropathy.
Farshchian N; Alavi A; Heydarheydari S; Moradian N
Cancer Chemother Pharmacol; 2018 Nov; 82(5):787-793. PubMed ID: 30105459
[TBL] [Abstract][Full Text] [Related]
8. Steroidogenic disruptive effects of the serotonin-noradrenaline reuptake inhibitors duloxetine, venlafaxine and tramadol in the H295R cell assay and in a recombinant CYP17 assay.
Islin J; Munkboel CH; Styrishave B
Toxicol In Vitro; 2018 Mar; 47():63-71. PubMed ID: 29100959
[TBL] [Abstract][Full Text] [Related]
9. Withdrawal Symptoms after Serotonin-Noradrenaline Reuptake Inhibitor Discontinuation: Systematic Review.
Fava GA; Benasi G; Lucente M; Offidani E; Cosci F; Guidi J
Psychother Psychosom; 2018; 87(4):195-203. PubMed ID: 30016772
[TBL] [Abstract][Full Text] [Related]
10. Serotonin-Norepinephrine Reuptake Inhibitors and the Risk of AKI: A Cohort Study of Eight Administrative Databases and Meta-Analysis.
Renoux C; Lix LM; Patenaude V; Bresee LC; Paterson JM; Lafrance JP; Tamim H; Mahmud SM; Alsabbagh MW; Hemmelgarn B; Dormuth CR; Ernst P;
Clin J Am Soc Nephrol; 2015 Oct; 10(10):1716-22. PubMed ID: 26231193
[TBL] [Abstract][Full Text] [Related]
11. A probable case of movement disorder (Tardive dyskinesia) due to duloxetine treatment.
Yılmaz R; Üstün D; Tuncer Uzun S; Reisli R; Türk Ş
Agri; 2018 Oct; 30(4):199-201. PubMed ID: 30403275
[TBL] [Abstract][Full Text] [Related]
12. Prurigo successfully treated with duloxetine hydrochloride.
Hashimoto T; Satoh T; Yokozeki H
Australas J Dermatol; 2019 Aug; 60(3):237-239. PubMed ID: 30675900
[TBL] [Abstract][Full Text] [Related]
13. Differences in the antinociceptive effects of serotonin-noradrenaline reuptake inhibitors via sodium channel blockade using the veratrine test in mice.
Yoshizawa K; Suzuki Y; Nakamura T; Takahashi Y; Makino K; Takahashi H
Neuroreport; 2021 Jun; 32(9):797-802. PubMed ID: 33994525
[TBL] [Abstract][Full Text] [Related]
14. Treatment of patients with diabetic peripheral neuropathic pain in China: a double-blind randomised trial of duloxetine vs. placebo.
Gao Y; Guo X; Han P; Li Q; Yang G; Qu S; Yue L; Wang CN; Skljarevski V; Dueñas H; Raskin J; Gu L
Int J Clin Pract; 2015 Sep; 69(9):957-66. PubMed ID: 25939897
[TBL] [Abstract][Full Text] [Related]
15. The safety of serotonin-noradrenaline reuptake inhibitors (SNRIs) in pregnancy and breastfeeding: a comprehensive review.
Bellantuono C; Vargas M; Mandarelli G; Nardi B; Martini MG
Hum Psychopharmacol; 2015 May; 30(3):143-51. PubMed ID: 25784291
[TBL] [Abstract][Full Text] [Related]
16. Venlafaxine-Associated Euprolactinemic Galactorrhea and Hypersexuality: A Case Report and Review of the Literature.
Warren MB
J Clin Psychopharmacol; 2016 Aug; 36(4):399-400. PubMed ID: 27219091
[No Abstract] [Full Text] [Related]
17. Venlafaxine induced QTc interval prolongation in a therapeutic dose.
Bavle A
Asian J Psychiatr; 2015 Aug; 16():63-4. PubMed ID: 26187237
[TBL] [Abstract][Full Text] [Related]
18. Serotonin Sensitivity and Withdrawal With Low-Dose Venlafaxine.
Khan S; Sivananthan M; Bacon O
Prim Care Companion CNS Disord; 2019 Feb; 21(1):. PubMed ID: 30817861
[No Abstract] [Full Text] [Related]
19. Serotonin syndrome, rhabdomyolysis and convulsion associated with drug interaction between venlafaxine and amoxicillin/clavulanic acid.
Fernández-Ferreiro A; Pose-Reino A; Martinez-Bahamonde F; Paris M; Guemas E; González-Barcia M; Lamas MJ
Actas Esp Psiquiatr; 2016 Sep; 44(5):193-202. PubMed ID: 27644102
[No Abstract] [Full Text] [Related]
20. Rhabdomyolysis With Acute Renal Failure Requiring Dialysis in McArdle Disease: A Role for the Antidepressant Venlafaxine?
Torner S; Tinel C; Soltani Z; Rifle G; Mousson C
J Clin Psychopharmacol; 2016 Aug; 36(4):406-8. PubMed ID: 27300253
[No Abstract] [Full Text] [Related]
[Next] [New Search]
